News | September 14, 2011

GE Launches Company to Enhance Development of Innovative Imaging Technology

September 14, 2011 – To accelerate and enhance the development of metabolic imaging and other innovative technology, GE has launched a new entity, Research Circle Technology Inc. (RCT). RCT’s vision is to create a strong alliance between GE’s scientists and the world’s leading universities, providing easy access to GE’s organic technology and wide scope of healthcare expertise in an open innovation structure.

Already, global leaders of imaging technology and disease detection research have explored potential applications for metabolic imaging technology:

  • University of California – San Francisco’s Surbeck Laboratory for Advanced Imaging has announced the groundbreaking results of a study utilizing GE’s 13-C (Carbon 13) technology to study prostate cancer. “This is the first time researchers have used this technology to conduct real-time metabolic imaging in a human patient, and represents a revolutionary approach to assessing the precise outlines of a tumor, its response to treatment and how quickly it is growing,” said Sarah J. Nelson, Ph.D., a professor of radiology and biomedical imaging at UCSF. Nelson is presenting the team’s findings at the World Molecular Imaging Conference (WMIC) in San Diego this week.
  • Scientists at Cancer Research UK’s Cambridge Research Institute have developed a technique to show the effectiveness of breast cancer treatment weeks earlier than current methods through metabolic imaging. According to lead researcher Professor Kevin Brindle, “There has been a need to develop imaging methods that can help detect treatment response more accurately than traditional methods and before tumors change size. Our new imaging method not only shows early evidence that treatment is working but could also help predict the long-term outcome. We expect that these techniques will have an impact for patients in the near future.”

Through RCT, GE looks to continue developing this innovative technology, providing the tools, services and solutions so that leading researchers can focus on their investigations into the biochemistry of metabolism and speed the discovery of potentially lifesaving knowledge. RCT will sell SpinLab polarizers as well as provide the licensing framework for partners to continue to develop the metabolic imaging applications. RCT helps enable GE to fully connect with the skills and knowledge of the research community, with the goal of transitioning technology from ‘bench to bedside’ more efficiently.

“The focused goal of RCT is open collaboration to bring hyperpolarization technology to the worlds’ leading researchers and enable their studies to better understand the biochemistry of life,” said Jonathan A. Murray, managing director, RCT. “The early results are very exciting and we are delighted to collaborate with this community to help bring this innovative technology to its full potential.”

For more information: www.gehealthcare.com

 

Related Content

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init